Valuation: Erasca, Inc.

Market Cap 4.98B 4.37B 4.13B 3.76B 7.05B 478B 7.1B 49.43B 19.14B 244B 18.71B 18.31B 784B P/E 2026 *
-14.4x
P/E 2027 * -21.7x
Enterprise Value 4.14B 3.63B 3.43B 3.12B 5.85B 396B 5.89B 41.01B 15.89B 202B 15.53B 15.19B 651B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day-1.86%
1 week-3.52%
Current month-20.30%
1 month-19.76%
3 months-4.68%
6 months-10.88%
Current year+283.06%
1 week 13.54
Extreme 13.535
15.78
1 month 13.54
Extreme 13.535
20.4
Current year 3.36
Extreme 3.36
24.28
1 year 2.02
Extreme 2.015
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.28
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer 66 10/08/2026
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
8/10/26 A Free

Chief Technology Officer

1,300,000 0.3745%
6/26/26 A Free

Director

29,888 0.0096%
4/1/26 A Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
-1.86%-3.52%+687.29%+572.17% 4.98B
-0.14%+4.33%+9.88%+31.73% 47.97B
-1.69%+1.48%+53.02%+33.59% 44.5B
+2.56%+7.34%+382.17%+594.81% 43.93B
+0.24%+2.85%+9.78%+89.54% 41.03B
-0.62%-1.11%+4.70%+46.02% 29.85B
-0.28%+1.07%+26.83%+152.91% 17.27B
-0.46%+1.20%+26.78%+41.32% 15.3B
-2.21%-4.70% - - 14.82B
+3.37%+9.21%+9.93% - 15.34B
Average -0.11%+1.76%+134.49%+195.26% 27.5B
Weighted average by Cap. +0.07%+2.75%+94.61%+164.68%

Financials

2026 *2027 *
Net sales - -
Net income -322M -282M -267M -243M -455M -30.84B -458M -3.19B -1.24B -15.76B -1.21B -1.18B -50.64B -228M -200M -189M -172M -323M -21.87B -325M -2.26B -877M -11.17B -857M -838M -35.91B
Net Debt -849M -745M -703M -641M -1.2B -81.33B -1.21B -8.42B -3.26B -41.55B -3.19B -3.12B -134B -762M -668M -631M -575M -1.08B -73.01B -1.08B -7.55B -2.93B -37.3B -2.86B -2.8B -120B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
25/09/26 $14.25 -1.86% 3,218,199
24/09/26 $14.52 +4.12% 6,266,868
23/09/26 $13.95 -10.32% 4,424,782
22/09/26 $15.55 +3.39% 4,766,263
21/09/26 $15.04 +1.83% 4,151,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.25USD
Average target price
24.11USD
Spread / Average Target
+69.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock